Dosage confusion at a production facility in Baltimore, which ruined approximately 15 million doses of Johnson & Johnson’s COVID vaccine, prompted the U.S. Food and Drug Administration to delay certification of the facility.
Employees of Emerging BioSolutions, a production plant in Baltimore, and a manufacturing partner of Johnson & Johnson and AstraZeneca, have reportedly mixed two doses of the vaccine and shipments have been suspended.
The offices and manufacturing plant of Emerg Biosolutions, which makes vaccines for AstraZeneca and Johnson & Johnson, are seen through a security fence on February 8, 2021, in Baltimore, Maryland. (Getty Images)
Johnson & Johnson’s vaccine deliveries have been delayed pending an FDA investigation.
U.S. officials have said the deterioration of the vaccine will not impact plans to provide enough vaccine to immunize every adult by May.
In a statement provided to Fox Business, Johnson & Johnson said it plans to deliver its vaccine at a rate of more than a billion doses by the end of 2021.
The company said quality control identified a batch of drug substance that did not meet Emerging Biosolutions’ quality standards, and that this batch was never advanced to the filling and finishing stages of its process. Manufacturing.